Skip to main content
Pharma Mar S.A. logo

Pharma Mar S.A. — Investor Relations & Filings

Ticker · PHM ISIN · ES0169501022 LEI · 959800QWKZ45ZQC2AV58 MC Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2024-12-30 Transaction in Own Shar…
Country ES Spain
Listing MC PHM

About Pharma Mar S.A.

https://pharmamar.com/en/

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Recent filings

Filing Released Lang Actions
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa de Recompra de Acciones en el periodo transcurrido entre el 23 de diciembre y el 27 de diciembre de 2024.
Transaction in Own Shares Classification · 100% confidence The document is a formal communication to the 'Comisión Nacional del Mercado de Valores' (CNMV, the Spanish securities market regulator) dated December 30, 2024. The subject is 'COMUNICACIÓN DE OTRA INFORMACIÓN RELEVANTE' (Communication of Other Relevant Information) specifically detailing transactions under a 'Programa de recompra de acciones' (Share repurchase program) conducted between December 23 and December 27, 2024. This directly reports on the company buying back its own shares. This activity aligns perfectly with the definition for 'Transaction in Own Shares' (Code: POS). Although it is a regulatory filing, POS is the most specific category available for share repurchase details.
2024-12-30 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is titled "MODELO DE NOTIFICACIÓN DE LAS OPERACIONES DE LAS PERSONAS CON RESPONSABILIDADES DE DIRECCIÓN Y DE LAS PERSONAS ESTRECHAMENTE VINCULADAS CON ELLAS" (Standard Form for Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with Them). This form explicitly details transactions (Compra/Buy) conducted by a director ('CONSEJERA') of the issuer (PHARMA MAR, S.A.). This type of filing, reporting insider trading or director's dealings, corresponds directly to the 'Director's Dealing' category.
2024-12-20 Spanish
La Sociedad finaliza el reclutamiento del estudio fase III LAGOON con Zepzelca® (lurbinectedina) para el tratamiento del cáncer de pulmón de célula pequeña.
Regulatory Filings Classification · 99% confidence The document is an official communication to the 'Comisión Nacional del Mercado de Valores' (CNMV, the Spanish securities market regulator) dated December 19, 2024. It is explicitly labeled as 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) and includes an attached press release detailing a significant operational milestone: the completion of patient recruitment for the Phase III LAGOON clinical trial for Zepzelca®. This type of announcement, which conveys material, non-public information to the market regulator and the public via a press release, typically falls under general regulatory disclosure requirements. Since it is not a full annual report (10-K), a quarterly report (IR), a specific management discussion (MDA), or a proxy statement (DEF 14A), and it is a formal regulatory filing announcing material news, the most appropriate classification is 'Regulatory Filings' (RNS), which serves as the general category for such mandatory disclosures that don't fit elsewhere. It is not an RPA because it contains the full substance of the news, not just an announcement that a report is available.
2024-12-19 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is titled "STANDARD FORM FOR NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM". This form explicitly details transactions (purchases of shares) made by a director ('CONSEJERA') of the issuer (PHARMA MAR, S.A.). This directly corresponds to the definition of Director's Dealing (insider trades) as per the provided classification list. The code for Director's Dealing is DIRS.
2024-12-19 Spanish
La Sociedad informa que llevará a cabo un programa de recompra de acciones propias
Regulatory Filings Classification · 99% confidence The document is a formal notification addressed to the 'Comisión Nacional del Mercado de Valores' (Spanish securities market regulator) dated December 18, 2024. The content explicitly details the agreement to carry out a 'programa de recompra de acciones propias' (share repurchase program). This action falls directly under the category of the company buying back or selling its own shares. The specific filing type that matches this activity is 'Transaction in Own Shares' (POS). Although it is a regulatory filing, POS is more specific than the general RNS category.
2024-12-18 Spanish
La Sociedad informa de la aprobación de los Reglamentos de la Comisión de Auditoría y de la Comisión de Nombramientos y Retribuciones y de Sostenibilidad, así como de la modificación del Reglamento de
Governance Information Classification · 98% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV), the Spanish securities market regulator, under the heading 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). The content details decisions made by the Board of Directors regarding the approval of specific commission regulations (Audit, Appointments/Remuneration/Sustainability) and the modification of the Board's internal regulations to comply with new Spanish laws (Ley Orgánica 2/2024). This type of mandatory disclosure regarding internal governance structure changes, board regulations, and compliance updates, especially when filed with the regulator, strongly suggests a governance or regulatory filing. Since it specifically deals with internal rules, board structure, and governance practices, the most fitting category is Governance Information (CGR). It is not a general earnings release (ER), a full annual report (10-K), or a simple announcement of a report (RPA), but rather the substance of a governance decision being reported.
2024-12-18 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.